Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Prescription of antibiotics at the point of care is very high in Southeast Asia. Simple tests can help health workers determine which patients actually need antibiotics, but we need to ensure that the benefits and advantages are clearly explained. In the long term, those tests could represent a sustainable alternative to the massive prescription of antibiotics in developing countries.

My name is Thomas Althaus, I’m a DPhil candidate at Oxford University but based in Southeast Asia. I’ve been mainly involved in a clinical trial based in Myanmar and northern Thailand with the objective to guide antibiotic prescription in primary care.

Prescription of antibiotics in Southeast Asia is major. We consider this region the epicentre of antibiotic prescription in the world and the immediate consequence of this massive antibiotic prescription is the mutation of bacteria to resistant strains. Primary care represents the major source of this antibiotic prescription and this is the reason why I was so interested in targeting primary care because it reaches a large amount of people in the community and at the same time there is no tool available to identify patients in need of antibiotics.

You have to understand that a typical health worker in primary care isn’t a doctor: it’s a nurse with limited clinical training, with probably more than one hundred patients a day. Health workers are facing a difficult, challenging question and they have no tool to answer this question. Fever can be caused by different pathogens. When a fever is caused by a virus, it doesn’t need an antibiotic to be treated. We call this treatment symptomatic, it means that you only need, for example, some paracetamol to control the fever and the body will handle the viral infection itself. On the opposite way, we also need to help identify patients who have an infection that requires an antibiotic, bacterial infection for example; you can die from a bacterial infection if you do not have antibiotics.

The CRP rapid test is very simple per se. It’s a test that tells you when to give an antibiotic or not. You can however imagine that patients might not be willing to comply to this test if they do not understand what it is. As an example, we were extremely surprised to see a patient asking for an antibiotic despite a negative test, because it took him a day to reach the facility and in terms of cost of transportation that was also very high for him. You cannot just simply expect people to comply to your prescription without explaining the test. What are the benefits and advantages of what we are doing, and this implies to know and to understand our population. It’s not about saying that antibiotics are bad; antibiotics are extremely useful but they’re precious and it’s a scarce resource we need to control. So it’s not a race to find new drugs, it’s a race to slow down the pace of antibiotic prescription.

Diagnosing malaria is extremely simple and cheap. We have rapid tests available everywhere for almost nothing and because of those tests being more and more negative because the disease is getting eliminated, we are now facing this new challenge that is once my malaria test is negative, what do I do with my patients? How can I manage a patient without malaria, with a fever? How can I figure out without having any access to laboratory if this patient needs an antibiotic or not? We also know that the most effective and funded research project trying to screen and to look for every pathogen do not discover more than let’s say 50% of the causes of fever. This means that even though you use your best diagnostic tool to investigate those causes of fever, in 50% of the cases you will never know what they have.

We know that antibiotic prescription in primary care is around 70% in Asia on average and bacterial infections should represent around 20%, so there’s a huge potential impact to have on health at this level of care. With such impact for such small investments, we could also allocate a bit of it to these no specific illness tests that could save a lot of lives and at the same time immediately impact antibiotic prescription at the point of care.

Thomas Althaus

Dr Thomas Althaus is a member of the Economic & Translational Research Group at MORU. He focuses on antimicrobial resistance, particularly the validation of point-of-care tests for inflammatory biomarkers. Those tests aim to guide the prescription of antibiotics in febrile patients attending primary healthcare settings in remote Southeast Asia.

More podcasts related to Global Health

Mike English: Health services that deliver for newborns

Basic hospital care may be key to saving newborn lives. Professor Mike English outlines a multidisciplinary project engaging policy-makers and practitioners in Kenya. This project demonstrated poor coverage of Nairobi’s 4.25 million population if a sick newborn baby needs quality hospital care. Using novel research approaches the team also identified how severe shortages of nurses contribute to poor quality of care for patients and negatively affect nurses themselves.

Tran Hien: Infectious diseases in the tropics

Although incidence of malaria has decreased in Vietnam, the burden of infectious diseases remains high and weighs heavily on the health care system. Clinical research aims to allow investments to go further: findings in the laboratory, tested in clinical trials and then applied to the community, help improve diagnosis and management.

Ronald Geskus: Sophisticated biostatistics for complex clinical research

The role of biostatisticians in clinical research is to contribute to trial design, by calculating sample size for example, and to help draw correct conclusions from the data, discriminating important information from noise. They are instrumental in the translation of a practical problem into a statistical model, and the translation of the result into practice.

Rogier Van Doorn: Research at OUCRU Hanoi

Antibiotics are widely used in Vietnam, leading to widespread antimicrobial resistance. Monitoring antibiotic use helps inform the government to change treatment guidelines and implement antibiotic stewardship programmes. This may also prevent the transmission of resistant bacteria outside the country.

Heiman Wertheim: Clinical research in low and middle-income countries

Drug resistant infections are a global crisis and we cannot focus on our own country only. Clinical trials in low and middle income countries where the burden is highest, as well as work with local communities and engagement with policy makers help influence public health policies.

Guy Thwaites: Tuberculosis meningitis

Tuberculosis meningitis affects a fractions of TB patients but causes high levels of mortality and morbidity. A recent trial at OUCRU showed that aspirin can greatly improve outcomes. Such trial is typical of the work done in our Vietnam units, where all the research is focussed on improving the outcome for patients directly.

Motiur Rahman: OUCRU laboratory management

OUCRU laboratories provide support to the unit’s extensive clinical research programme, from level 2 laboratory to SAPO 4 laboratory for high-risk pathogens responsible for zoonotic infections. Early diagnosis and detection of antimicrobial resistance helps prescribe the right medicine in time, contributing to better patient management.

Raph Hamers: Developing collaborative clinical trials in Indonesia

Indonesia is a very populous country with a huge burden of infectious diseases such as TB, malaria, HIV and CNS infections. Running clinical trials requires high levels of expertise, currently developed and strengthened by institutions such as IOCRL (Universities of Indonesia and Oxford Clinical Research laboratory). Better collaborations will also help great ideas make a bigger impact.

Jeremy Day: Central nervous system and HIV infections in Vietnam

Brain infections such as meningitis and encephalitis are highly debilitating diseases, and an accurate diagnostic is essential to give patients the best treatment available. For cryptococcal meningitis, clinical trials focus on prevention, for an early diagnosis, and novel ways to use existing treatments or repurpose old drugs.

Abhilasha Karkey: Connecting research with communities in Nepal

Antimicrobial resistance is a huge burden in Nepal, particularly in hospitals where many nosocomial infections are caused by resistant pathogens. With limited resources, little infection controls and proper guidelines in place, finding out the main risk factors helps reduce infection rates within a hospital and better target vaccination campaigns.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.